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Abstract
In cancer patients pervasive systemic suppression of Dendritic Cell (DC) differentiation and maturation can hinder
vaccination efficacy. In this study we have extensively characterized migratory DC subsets from human skin and studied
how their migration and T cell-stimulatory abilities were affected by conditioning of the dermal microenvironment through
cancer-related suppressive cytokines. To assess effects in the context of a complex tissue structure, we made use of a near-
physiological skin explant model. By 4-color flow cytometry, we identified migrated Langerhans Cells (LC) and five dermis-
derived DC populations in differential states of maturation. From a panel of known tumor-associated suppressive cytokines,
IL-10 showed a unique ability to induce predominant migration of an immature CD14+CD141+DC-SIGN+ DC subset with low
levels of co-stimulatory molecules, up-regulated expression of the co-inhibitory molecule PD-L1 and the M2-associated
macrophage marker CD163. A similarly immature subset composition was observed for DC migrating from explants taken
from skin overlying breast tumors. Whereas predominant migration of mature CD1a+ subsets was associated with release of
IL-12p70, efficient Th cell expansion with a Th1 profile, and expansion of functional MART-1-specific CD8+ T cells, migration
of immature CD14+ DDC was accompanied by increased release of IL-10, poor expansion of CD4+ and CD8+ T cells, and
skewing of Th responses to favor coordinated FoxP3 and IL-10 expression and regulatory T cell differentiation and
outgrowth. Thus, high levels of IL-10 impact the composition of skin-emigrated DC subsets and appear to favor migration of
M2-like immature DC with functional qualities conducive to T cell tolerance.
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Introduction
Dendritic cells (DC) are the major class of antigen presenting
cells (APCs) regulating adaptive immunity. In the steady state,
migratory immature DC from peripheral tissues take up antigen
but lack the capacity to promote functional T cell-mediated
immune responses. In response to activation signals, DC migrate
to draining Lymph Nodes (LNs) and mature into potent immune-
stimulatory APC that can drive T cell expansion and differenti-
ation [1,2]. As it is lined by a dense network of DC with ready
access to lymph vessels, skin is a preferred site for the delivery of
tumor vaccines [3]. Unfortunately, tumors exert powerful systemic
immune suppression, resulting in impaired differentiation and
activation of DC, possibly also impacting DC functionality in the
skin.
Skin DC consist of two major migratory subsets: epidermis-
derived Langerhans Cells (LC) and Dermal DC (DDC). The latter
can be roughly divided into CD1a+ and CD14+ subsets [4]. All
these subsets migrate to draining LN, even in the steady state, and
so maintain peripheral tolerance [4]. Upon activation their
migration rate increases and they acquire a mature phenotype,
allowing the activation and expansion of specific T cells [4,5]. LC
have been suggested to preferentially activate Cytotoxic T
Lymphocytes (CTL), whereas CD14+ DDC have been implicated
in the priming of B cell responses [6]. However, these assertions
are mostly based on findings from murine studies or from in vitro
studies with LC or CD14+ DDC-like cells derived from CD34+
precursor cells. Functional studies with primary DC from human
skin are complicated by their low numbers and therefore sparse.
Nevertheless, some valuable information about the ability of
human skin-associated DC subsets to direct T cell responses has
been obtained.
Peiser et al. showed low-level release of IL-12p70 by LC, freshly
isolated from epidermal sheets, as compared to monocyte-derived
DC (MoDC) [7]. In line with this observation, others have
suggested that the LC’s supposed superior CTL activating ability
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might derive from its release of IL-15 or CD70 expression rather
than IL-12p70 secretion [8–10]. One study demonstrated a
superior ability of LC over DDC to induce both Th1 and Th2
responses [11], whereas others have shown primary human LC to
skew Th cell responses (including conventional variant ab-T cells
restricted through CD1a) to a Th22-type response, characterized
by IL-22 release in the absence of IL-17 [12,13]. The T cell
skewing abilities of DDC appear to be determined by a balance of
factors in the microenvironment. Larregina and co-workers have
shown in a number of reports that human DDC can skew Th cells
to either a Th1, a Th2, or a Th17 profile, depending on their
conditioning, number and activation state [14–16]. In the steady
state LC are primarily responsible for the homeostatic prolifera-
tion of skin-resident memory T cells, most notably CD4+
regulatory T cells (Tregs) [17]. Recently, CD14+ DDC from
human skin have been shown to induce Tregs [18]. As yet, it is
unclear how tumor-mediated conditioning of the skin will impact
the ability of the DC located there to skew and direct T cell
responses. In this regard, modulation of the cutaneous cytokine
balance may prove crucial to the efficacy of intradermally (i.d.) or
epicutaneously applied cancer vaccines.
T cell activation by mature DC is a carefully coordinated
process, involving a regulated sequence of events leading to DC
migration, activation, cytokine release, and antigen presentation.
For optimal immune activation to occur, these events need to be
tightly controlled, both spatially and chronologically. In view of
these considerations, we employed an organotypic human skin
explant culture system to characterize migratory DC subsets and
to study cytokine-related modulation of their phenotype and
function and how this impacts CD4+ and CD8+ T cell activation
and differentiation. Our results point to IL-10 as a major
candidate effector of tumor-related modulation of DC subset
migration from human skin, resulting in prevailing migration of
CD14+BDCA3/CD141+ DC that acquire an immunoregulatory
phenotype and cytokine release profile with detrimental effects on
cell-mediated immunity.
Materials and Methods
Skin explant preparation and culture
Healthy human skin specimens were obtained after verbal
informed consent at the time of hospital admission from patients
undergoing corrective breast or abdominal plastic surgery at the
VU University medical center (VUmc, Amsterdam, The Nether-
lands) or at the Tergooi hospital (Hilversum, The Netherlands)
and used in an anonymous fashion. As this does not entail
additional interventional procedures and applies to biological
materials that would otherwise be disposed of, verbal consent
sufficed according to Dutch national guidelines; patients that
objected to this procedure signed a statement to this effect, in
accordance with the ‘‘Code for Proper Use of Human Tissues’’ as
formulated by the Dutch Federation of Medical Scientific
Organizations (www.fmwv.nl) and following procedures approved
by the IRB [19]. Materials from patients with breast cancer
participating in clinical trials were collected after written informed
consent according to protocols approved by the VUmc IRB
(IRB00002991; IORG number 0002436).
Cytokines were i.d. injected in surgical healthy skin specimens
with a Micro-Fine Insulin syringe (0.33 mm (29 G)612.7 mm
needle, BD, Franklin Lakes, NJ) in a total volume of 20 ml serum-
free medium. The following amounts of cytokines were injected
per explant: 100 ng GM-CSF (Berlex Laboratories Inc. Montville,
NJ), 1000 IU IL-4, and 10 ng IL-10 (Strathmann Biotec,
Hamburg, Germany). These amounts were based either on
optimal effects or on maximal sub-toxic doses found upon titration
[19]. At the site of injection a 5 mm-diameter urtica appeared and
an exact punch biopsy of 6 mm was taken. The biopsy was lifted
from the specimen with a sterile forceps and with sterile scissors
the dermis was cut at a depth of 2–3 mm to obtain skin explants.
Biopsies were placed in 1 ml culture medium (i.e. IMDM
containing 5% Human Pooled Serum (Sanquin Blood Supply,
Amsterdam, The Netherlands), supplemented with 100 IU/ml
sodium penicillin (Yamanouchi Pharma), 100 mg/ml streptomycin
sulfate (Radiumfarma-Fisiopharma), 2 mM L-glutamine (Invitro-
gen Life Technologies), and 0.01 mM 2-ME (Merck). Per
experimental condition 10–20 explants were cultured. After a
culture period of 48 h the skin explants were discarded. Migrated
cells were harvested at these or later time points and used for
further analyses –no additional cytokines were added to the
cultures. Between 1998 and 2002, skin from mastectomy material
was excised by an experienced pathologist from patients with
breast cancer at the VUmc in Amsterdam, The Netherlands
[20,21]. Skin was i.d. injected with 20 ml serum-free medium.
Explants were taken and cultured as described above, after which
migrated cells were harvested and analyzed by flow cytometry.
From four patients with Locally Advanced Breast Cancer (LABC,
i.e. stage IIB with a primary breast tumor larger then 5 cm, IIIA
or IIIB according to AJCC criteria), skin was collected and
cultured subsequent to neoadjuvant chemotherapy with doxoru-
bicin and cyclophosphamide [20,21]. Partial tumor responses
according to RECIST criteria were observed in all four patients; in
three patients only microscopic evidence of disease remained
whereas in one patient the tumor shrunk from a volume of
23617 cm to a diameter of 1.5 cm.
HLA-A2 typing of the skin explants
Medium-injected 6 mm biopsies (10 per condition) were placed
in 10 cm diameter culture dishes containing 15 ml 0.05% trypsin
(Invitrogen GIBCO, Paisley, Scotland) for 4–5 hr at 37uC, 5%
CO2. The epidermis was separated with tweezers, washed with
IMDM 10% FCS and pushed through a 100 uM-pore nylon
strainer (Falcon-BD biosciences, San Jose, CA) with the plunger of
a 2 ml syringe to obtain a single-cell suspension. The cell
suspensions were used for HLA-A2 typing by flowcytometric
analysis as described below, by use of HLA-A2 specific monoclo-
nal antibodies (mAb); used clones were BB7.2 and MA 2.1 from
the American Tissue Culture Collection (ATCC, Rockville, MD).
Flow cytometry
Phenotypic analyses were performed by flow cytometry. Cells
were washed in PBS supplemented with 1% BSA and 0.02%
NaN3 (PBA) and incubated for 30 min. at room temperature in
the presence of appropriate dilutions in PBA of FITC, PE, PerCP
or APC fluorochrome-conjugated specific mAbs to CD3, CD4,
CD11c, CD14, CD25, CD1a, B7–H1 (i.e. Programmed Cell
Death-Ligand 1, PD–L1), DC-SIGN, CD80, CCR7, CD163 (BD,
San Jose, CA), BDCA3 (Miltenyi, Bergisch Gladbach, Germany),
E-cadherin, Langerin, or CD83 (Beckman Coulter Immunotech),
FoxP3 (eBioscience, San Diego, CA) or corresponding isotype-
matched control mAbs (BD, San Jose, CA). For intracellular
staining of Langerin, E-Cadherin and DC-SIGN, surface markers
CD14, CD1a and CD11c were first stained as described above.
Subsequently, cells were fixed and permeabilized using the BD
Fix-Perm kit, following manufacturer’s guidelines. Intracellular
staining with PE-labeled DC-SIGN, Langerin, E-Cadherin or
control IgG1 was performed for 30 minutes at 4uC in 16
permeabilization buffer. Cells were washed once with 16
permeabilization buffer and once with FACS buffer before
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analysis. The cells were subsequently analyzed, using a FACSCa-
libur and Cellquest-Pro FACS analysis software (BD, San Jose, CA).
IL-10 and IL-12p70 release
DC migrated from human skin were harvested at the indicated
time points and analyzed for functional IL-12p70 and IL-10
release as described [22]. Briefly, 16104 DC were incubated with
16104 J558-CD40L cells in the presence of 1000 U rhIFNc/ml
(Sanquin Blood Supply, Amsterdam, The Netherlands) in 100 ml
IMDM with 10% FCS. After 24 h, the supernatants were
collected and stored at 220uC until further analysis. IL-12p70
and IL-10 concentrations were determined by capture ELISA as
previously described [23].
Th and Treg differentiation assays
40,000 skin-emigrated DC were incubated with 0.5 mg/ml anti-
CD3 (OKT-3, eBioscience, San Diego, CA) in 200 ml complete
medium (i.e. IMDM supplemented with 10% fetal bovine serum
(FBS; HyClone), 100 IU/ml sodium penicillin, 100 mg/ml strep-
tomycin sulfate, 2 mM L-glutamine, and 0.01 mM 2-ME for 15
minutes at 4uC. After incubation, the DC were co-cultured with
20,000 CD4+CD252 T cells (isolated by magnetic bead separation
using the untouched CD4 isolation kit and anti-CD25 beads from
Miltenyi, Bergisch Gladbach, Germany, according to the manu-
facturer’s instructions) for 14 days. At day 7, 10 U/ml IL-2
(Strathmann Biotec, Hamburg, Germany) was added to the
cultures. On day 14, T cells were harvested and analyzed by
flowcytometry for CD3, CD4, CD25 and FoxP3 expression as
previously described [24] or 50,000–100,000 T cells were
stimulated with 0.5 mg/ml anti-CD3 (OKT-3) and 0.5 mg/ml
anti-CD28 (clone 15E8) overnight. Supernatants were collected
and were analyzed for cytokines secreted by the Th cells using a
Th1/Th2/Th17 CBA kit (BD Biosciences, San Jose, CA) and an
IL-22 ELISA kit (R&D systems, Minnesota, USA), following the
manufacturer’s instructions. At that time stimulated Th cells were
harvested and RNA isolated to also assess transcript levels of Th1-,
Th2-, Th17-, Th22-, or Treg-associated transcription factors and
cytokines. In an alternative protocol 10,000 migrated and OKT3-
loaded DC were cultured for 7 days with 16105 peripheral blood
lymphocytes and analyzed by flowcytometry for CD3, CD4, CD25
and FoxP3 expression. In addition, at that time the cells were
incubated for 4 hours with 50 ng/ml PMA and 500 ng/ml
ionomycin in the presence of 0.5 ml/ml brefeldin A (GolgiPlug, BD
Biosciences), stained for CD3 and CD4, and for FoxP3 and IFNc
(BD, San Jose, CA) after permeabilisation using the eBioscience Treg
staining kit and subsequently analyzed, using a FACSCalibur and
Cellquest-Pro FACS analysis software (BD, San Jose, CA).
RNA Isolation and cDNA Synthesis
Total RNA was isolated using the RNeasy Plus Micro kit
(Qiagen, Hilden, Germany). Contaminating genomic DNA was
removed by using the gDNA Eliminator spin colums from the kit.
The concentration and purity of the RNA was analyzed using the
NanoDrop ND-1000 (Thermo Scientific, Wilmington, DE 19810
USA). cDNA was synthesized using oligo(dT)20 primers and the
SuperScript III First-Strand Synthesis System for RT-PCR
(Invitrogen, Carlsbad CA) according to the manufacturer’s
instructions. Input of RNA was 240 ng. After cDNA synthesis
nuclease-free water was added up to a final volume of 80 ml.
Real-time qRT-PCR
Transcripts were quantified by real-time quantitative polymer-
ase chain reaction (qPCR) using an ABIPRISM 7900 Sequence
Detector and pre-designed TaqMan Gene Expression Assays and
reagents according to manufacturer’s instructions (Applied Bio-
systems, Foster City, CA), as described previously [24]. Probes
with the following Applied Biosystems assay identification
numbers were also used: TBX21 (Tbet), Hs00203436_m1;
GATA3, Hs00231122_m1; FOXP3, Hs00203958_m1; RORC1-
2, Hs00172858_m1; RORC10-11, Hs01076112_m1, IL17A,
Hs00174383_m1; human HPRT1 Endogenous Control
(4333768T; Applied Biosystems) served as reference housekeeping
gene. We validated all primers according to protocol. Mean
relative mRNA expression was calculated using Pfaffl method
[25].
CD8+ T cell induction
To determine the capacity of skin explant-emigrated DC to
prime specific CD8+ T cells, 2-day migrated DC were loaded with
1 mg/ml Mart-126–35L peptide (ALGIGILTV, obtained from
LUMC, Leiden The Netherlands) in the presence of 3 mg/ml
b2-microglobulin (Sigma-Aldrich) for 4–5 h at room temperature.
Multiple bulk cultures of 16106 HLA-A2-matched CD8b+ T cell
precursors were subsequently cultured with 56104 MART-126L–35
peptide-loaded allogeneic skin-emigrated DC and with 16106
irradiated (80 Gy) CD8b–depleted autologous PBMC in Yssels
medium supplemented with 1% human AB serum (ICN
Biochemicals), 10 ng/ml IL-6, and 10 ng/ml IL-12 (R&D systems
Inc,) in a 24-well tissue-culture plate. At day 1, 10 ng/ml IL-10
was added. After 10 days, CD8+ T cell cultures were analyzed for
the presence of MART-126L–35-specific CD8
+ T cells by tetramer
(Tm) staining as described previously [26]; cultures with Tm
percentages exceeding 0.1% were considered positive. At this time,
CD8+ T cells were restimulated with 1*10E5 JY cells, loaded with
10 ng/ml MART-126L235 peptide, and cultured for an additional
seven days in the presence of 5 ng/ml IL-7 (Strathmann Biotec).
After this additional round of restimulation, Tm positive cultures
were pooled per experimental condition and the functional avidity
of the Mart-1 primed CD8+ T cells was determined.
CD8+ T cell functional avidity analysis
CD8+ T cells were cultured with titered peptide-loaded JY cells
at an effector: target ratio of 2:1 in 96-well round-bottom plate in
the presence of 0.5 ml of GolgiPlug (BD Biosciences). After 5 h,
cells were harvested, washed, and stained with allophycocyanin
(APC)-labeled tetramer, and PE-labeled antiCD8 mAb. After
fixation with Cytofix/Cytoperm solution and permeabilization
with Perm/Wash solution (both from BD Biosciences), cells were
labeled with FITC-conjugated anti-IFNc mAb (BD Biosciences).
Stained cells were analyzed on a FACSCalibur with Cellquest-Pro
software (Becton Dickinson, San Jose, CA). Functional avidity was
expressed as peptide concentration at which half maximal
percentage of IFNc-expressing CD8+ T cells was detected, as
described previously [26].
Statistical analysis
DC subset frequencies and marker expression levels, cytokine
release levels, transcript levels, and specific T cell frequencies were
compared between conditions using either the (paired) T test or
the (repeated measures) one-way ANOVA or Friedman test with
respective post-hoc Tukey or Dunn’s multiple comparison
analyses. Fractions of tetramer positive cultures were compared
by the Fisher’s Exact test and Pearson correlations between
transcript levels of T cell transcription factors and cytokines were
calculated. Prism 4.0 statistical software (GraphPad Software Inc.,
La Jolla, CA) was used. Differences and correlations were
considered significant when P,0.05 in two-sided analyses.
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Results
Predominant CD14+ DC migration from IL-10-
conditioned or breast cancer-associated skin
We previously reported that i.d. cytokine levels influenced the
subset composition of migratory DC from human skin, with DC-
stimulatory cytokines (GM-CSF and IL-4) inducing predominant
migration of CD1a+ LC and/or DDC with a mature phenotype,
and IL-10 inducing predominant migration of CD14+ DDC with
an immature phenotype [19]. Here we confirm these findings (see
Fig. 1A, n= 13–19) and additionally show that 48 h-migrated DC
from skin explants taken from breast tumor-overlying skin, showed
similar low frequencies of mature CD1a+ migratory DC and high
frequencies of immature CD14+ subsets as observed subsequent to
IL-10 conditioning (n = 6, Fig. 1A, 1B). CD1a+, CD1a+CD14+,
and CD14+ DDC are subsets that range from more to less mature
respectively [19]; we found a clear shift to a predominance of
immature CD14+ subsets among DC migrated from breast tumor-
overlying skin (Fig. 1C). Importantly, the migrated DC subset
distribution appeared to be normalized subsequent to neo-
adjuvant chemotherapy, confirming a relation to tumor load of
the observed aberrant subset distribution (n = 4, Fig. 1A; for
information on tumor response we refer to the Materials and
Methods section). Representative CD1a vs CD14 FACS dot plots
from breast cancer patients with and without neoadjuvant
chemotherapy, illustrating the shifting DC subset distributions,
are shown in Fig. 1C and 1D, respectively. Accompanying the
tumor-associated shifts in the CD1a/CD14 frequencies, CD83
frequencies also shifted in concordance with a mature state of the
CD1a+ DC and an immature state of the CD14+ DC (Fig. 1E).
While it proved technically unfeasible to determine the responsible
factor for the observed CD14+ subset skewing in cancer-
conditioned explants (due to the limited size of mastectomy-
derived skin samples), testing of a panel of six well-known cancer-
associated suppressive cytokines (as well as PGE2, data not shown)
clearly pointed to a unique role for IL-10 in this respect (see
Fig. 1F).
DC migrating from human skin comprise at least six
phenotypically distinct subsets
We next set out to further delineate the various migratory skin
DC subsets and how dermal cytokine conditioning affected their
phenotype and migration rates. Based on CD1a, CD14, and
CD11c expression (Fig. 2A) as well as subset-specific markers
(Fig. 2B–F), six different populations or subsets were identified
among DC that had migrated from 48 h-cultured full-thickness
human skin explants. As shown in Fig. 2B and 2C, near-exclusive
expression of intracellular Langerin and E-Cadherin on the small
CD1ahi population (with notably lower CD11c expression levels
than the other subsets –Fig. 2A) clearly identified it as epidermis-
derived LC (subset 1). Of note, Langerin expression was also
observed on a small subpopulation of the more frequent CD1a+
DDC (subset 2). Intracellular DC-SIGN expression (up-regulated
by i.d. administration of GM-CSF+IL-4) was observed in all five
DDC subsets, but reached highest frequencies in the CD14+
subsets (subsets 3 and 4) and the CD1a2CD142 (double negative,
DN) subset with high CD11c expression levels (subset 5) (see
Fig. 2A and 2D). Of note, these subsets also displayed the highest
expression levels of the C-type Lectin BDCA3/CD141 (a.k.a.
Thrombomodulin, Fig. 2E), a marker recently linked to DC
subsets with particularly powerful cross-priming abilities [27,28].
CD163, a macrophage marker associated with the M2 regulatory
phenotype [29], was selectively expressed on the CD14+ subsets
and up- and down-regulated by i.d. conditioning with IL-10 or
GM-CSF+IL-4, respectively (see Fig. 2F).
Cytokine conditioning affects migration rates of skin DC
subsets and overall immune stimulatory versus inhibitory
DC phenotype
The various DC subsets displayed different states of maturation
as evidenced by differential expression levels of maturation and co-
stimulatory markers (see Fig. 3A). Based on the expression of
CD83, LC and CD1a+ DDC (subsets 1 and 2) clearly displayed a
superior maturation state over the other subsets. Conversely, the
CD14+ DDC subsets and the DN CD11chi DDC subset (subsets
3–5) were the least mature. Similar expression patterns were
observed for CD80 (Fig. 3A) and CD40 and CD86 (not shown).
Remarkably, the over-all maturation state of the various subsets, as
judged by the maturation–associated markers CD83 and CD80,
was hardly affected by the i.d. delivery of either the stimulatory
cytokine cocktail GM-CSF+IL-4 or the inhibitory cytokine IL-10,
both in terms of percentage positive cells and in mean fluorescence
intensity, see Fig. 3A and Fig. 4 respectively. Interestingly, a highly
significant reverse correlation between CD83 expression and
expression of either DC-SIGN or BDCA3 on all six DC subsets
migrated under steady state (i.e. medium control) conditions
(Fig. 3B) identified the latter two as reliable markers for an
immature state of migratory skin DC. In contrast to co-stimulatory
markers, the co-inhibitory molecule PD-L1 (B7–H1) was up-
regulated on all DDC subsets by both GM-CSF+IL-4 and IL-10
(see Fig. 3A and 4). Remarkably, this was not the case for LC;
indeed upon i.d. delivery of GM-CSF+IL-4 migratory LC
significantly down-regulated PD-L1 levels (Fig. 4). In addition,
intensity levels of intracellularly stained DC-SIGN were strongly
up-regulated on all migrated DDC subsets upon dermal GM-
CSF+IL-4 conditioning. High CD163 levels that were further up-
regulated by IL-10, were detected specifically on both CD14+
DDC subsets, consistent with a regulatory macrophage-like
phenotype (Fig. 4).
While i.d. delivery of cytokines did not alter the maturation state
of the individual DC subsets -as judged on the basis of CD83 and
CD80 expression, it did alter their relative contribution to the total
migrated DC population (Fig. 5A). As compared to medium
controls, i.d. conditioning by GM-CSF+IL-4 resulted in increased
frequencies of the more mature LC and CD1a+ DDC subsets,
while i.d. conditioning by IL-10 led to increased frequencies of the
immature CD1a+CD14+ and CD14+ DDC subsets (see high-
lighted areas in Fig. 5A). In Fig. 5B cytokine-modulated levels of
the co-stimulatory markers CD83 and CD80 are shown side by
side with corresponding levels of the co-inhibitory molecule PD-L1
and the regulatory M2-associated macrophage marker CD163 for
each of the individual LC and CD1a and/or CD14+ DDC subsets.
The combination of consistently low levels of co-stimulatory
markers (CD83 and CD80) and up-regulated PD-L1 and CD163
levels most likely signify a T cell-suppressive make-up of the
CD14+ DDC subsets, in particular upon i.d. IL-10 modulation.
The preponderance of the CD14+ DDC subsets among skin-
emigrated DC subsequent to i.d. IL-10 delivery would thus predict
poor overall T cell activation. In contrast, high levels of co-
stimulatory levels on the LC and CD1a+ DDC subsets might
ensure T cell activation, despite up-regulated PD-L1 levels upon
cytokine modulation. To ascertain the actual effects of the
observed cytokine-induced shifts in DC subset composition and
phenotype on subsequently induced T cell responses, we next
investigated the ability of the skin-emigrated DC to support and
skew Th cell differentiation and to prime and expand specific
CD8+ effector T cells.
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Figure 1. Dermal cytokine conditioning modulates subset distribution among skin-emigrated DC. A) Pie charts present the distribution
of 2-day skin-emigrated CD1a+, CD14+ (including CD1a+CD14+) and double negative (DN) DC subsets for the indicated test conditions. Breast cancer
explants were taken from tumor-overlying skin from chemonaive patients undergoing mastectomy. Post-chemo skin explants were similarly obtained
from neoadjuvant chemotherapy-treated breast cancer patients. B) Distribution of Langerhans cells (LC) or CD1a+ and/or CD14+ dermal DC (DDC)
among DC migrated from healthy donor explants or from explants taken from skin overlying breast tumors. Representative CD1a/CD14 FACS
analyses of DC migrated from C) breast cancer patients and D) from breast cancer patients treated with neoadjuvant chemotherapy (percentages of
the different subsets are indicated). D) Frequencies of CD1a/CD14/CD83 positive DC among the indicated test groups. Indicated statistical
significance levels were relative to medium controls in repeated measures 1-way ANOVA (cytokine experiments) or unpaired Student T tests (breast
cancer experiments). E) Known tumor-associated suppressive cytokines were i.d. injected and migrated DC subsequently harvested from skin explant
cultures 2 days later; n = 3–9. CD14+ DC frequencies were significantly upregulated by IL-10 only (P,0.01, denoted by asterisks).
doi:10.1371/journal.pone.0070237.g001
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Figure 2. Human skin explant-emigrated DC consist of at least six subsets. A) DC, migrated from 2-day cultured skin explants, were gated
by high Forward and Side Scatter properties and by differential CD1a, CD14 and CD11c expression levels (displayed by dot plots) to distinguish six
separate subsets as listed at the bottom of the figure. Prior to culture, explants were i.d. injected with plain medium, GM-CSF+IL-4, or IL-10 as
indicated. Percentages of the DC subsets corresponding to the depicted gates are shown. B–F) Expression levels of the indicated markers (in %
positive cells, mean6s.e.m.) are shown within each of the DC subsets and for all three test conditions; n = 4.
doi:10.1371/journal.pone.0070237.g002
Figure 3. Human skin-emigrated DC subsets display different maturation states. A) DC subsets (designated 1–6, phenotypic definitions
listed), migrated from 2-day cultured skin explants, display varying levels of the maturation-associated markers CD83, CD80, and PD-L1 n= 4 (in %
positive cells, mean6s.e.m.). B) Significant reverse correlations between subset expression levels of DC-SIGN and BDCA3/CD141 on the one hand and
CD83 on the other, demonstrate DC-SIGN and BDCA3 to be valid markers for immature skin-derived DC subsets under steady-state conditions (i.e.
migrated from serum-free medium injected explants); n = 4.
doi:10.1371/journal.pone.0070237.g003
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Modulation of IL-10 and IL-12p70 release
As an indication of their ability to support durable T cell
differentiation, migrated (and thoroughly washed) DC were tested
for CD40L-stimulated release of IL-12p70 and IL-10 at two and
seven days after start of migration (Fig. 6A). High levels of IL-10
(around 400 pg/ml) were only released by DC emigrated from IL-
10-conditioned explants and exclusively in early stages of
migration (day 2). Lower levels of IL-10 production (#100 pg/
ml) were observed for the other test conditions at this time
(Fig. 6A). IL-10 release in any of the tested conditions had dropped
below the detection limit of the employed ELISA by day 4 (data
not shown). Of note, IL-12p70 release followed reverse kinetics
with highest levels at day 7, which were significantly elevated upon
i.d. delivery of GM-CSF+IL-4 (see Fig. 5A). Lower, but still
elevated, levels for the latter condition were detected at day 2
(mean 125 pg/ml (range 15–305) vs. 6.5 pg/ml (range 0–29) for
medium controls, P,0.05) and 7.0 pg/ml (range 0–27) in the IL-
10 condition. In order for the observed IL-12p70 release to result
in proper type-1 T cell activation, the skin-emigrated DC need to
preserve their mature T cell-stimulatory phenotype as well as their
ability to home to the paracortical T cell areas of the lymph node
(mediated by the CCR7 chemokine receptor). We therefore
related expression of CD83 and CCR7 at day 7 to the IL-12:IL-10
ratio. As shown in Fig. 6B, significantly higher IL-12:IL-10 release
Figure 5. T cell-stimulatory or –inhibitory phenotypic features of the CD1a+ and/or CD14+ skin-emigrated LC and DDC subsets and
their relative distribution upon cytokine modulation. A) DC subset frequencies among 2-day skin-emigrated DC from skin explants i.d.
injected with medium, GM-CSF+IL-4 or IL-10, prior to migration; n = 4 (mean6s.e.m.). High-lighted areas contain results for the CD1a and/or CD14
positive LC and DC subsets shown in (B). B) Side-by-side comparison of the mean fluorescence intensity levels of the co-stimulatory markers CD83
and CD80 and the inhibitory marker PD-L1 and the M2 regulatory macrophage-related marker CD163 per LC and DDC subset with and without
cytokine modulation; n = 4, *P,0.05, **P,0.01 by paired t-test, medium versus cytokine conditions.
doi:10.1371/journal.pone.0070237.g005
Figure 4. Expression (fluorescence intensity) levels of co-stimulatory, co-inhibitory or subset-defining markers on skin-emigrated
DC subsets upon stimulatory or inhibitory cytokine modulation. DC subsets (phenotypic definitions listed), migrated from 2-day cultured
skin explants i.d. injected with either medium (open bars) or GM-CSF+IL-4 or IL-10 (closed bars), display varying levels of the maturation-associated
markers CD83, CD80, and PD-L1 or the subset defining markers DC-SIGN, BDCA3 and CD163; n = 4 (in mean fluorescence intensity [MFI], mean6s.e.m;
NB: isotype control fluorescence levels of all subsets never exceed MFI of 5). *P,0.05, **P,0.01 by paired t-test, medium versus cytokine conditions.
doi:10.1371/journal.pone.0070237.g004
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ratios favorable to immune activation were observed at day 2 and
7 for DC migrated from explants conditioned by GM-CSF+IL-4
(predominantly CD1a+), and were related to a preserved
expression at day 7 of CD83 and CCR7. In contrast, DC
migrated from IL-10-conditioned skin (predominantly CD14+)
displayed low IL-12:IL-10 ratios and expressed neither CD83 nor
CCR7.
Cytokine-mediated conditioning of the dermis: effects on
Th cell differentiation
We next studied the ability of IL-10-modulated skin DC to skew
differentiation of allogeneic Th cells. To this end migrated DC
were pre-loaded with anti-CD3 and cultured with CD252 Th cells
over a period of 14 days. Next, the Th cells were restimulated with
anti-CD3 and anti-CD28 for 24 h and supernatants and mRNA
were subsequently obtained to determine cytokine release and Th
cytokine and transcription factor transcript levels. DC that had
migrated from IL-10 conditioned explants induced poor Th cell
expansion rates (Fig. 7A) with an apparent Th2 switch and
decreased release of IL-22 (Fig. 7B). Moreover, they induced
significant increases in IL-10 release and transcription, concom-
itant with increased FoxP3 mRNA expression levels (Fig. 7C).
Indeed, IL-10 and FoxP3 transcript levels were significantly
correlated (r2 0.748, P,0.006, data not shown). These data are
consistent with the induction of potentially suppressive Tr1-like
cells by CD14+ DDC emigrated from IL-10 conditioned skin. This
notion was further supported by a significant correlation between
both FoxP3 and IL-10 transcript levels and frequencies of
migrated CD1a+CD14+ DDC, i.e. subset 3, which also expressed
CD141 (Fig. 2, Fig. 4) and the PD-L1 expression levels and
migration rate of which were both notably increased by IL-10
modulation (Fig. 5A,B). In contrast, an inverse trend was observed
for CD1a+ DDC that lacked CD14 expression and displayed high
co-stimulatory levels, see Fig. 7D. Of note, in 7-day co-cultures of
Figure 6. Dermal cytokine conditioning modulates IL-10 and IL-12p70 release by skin-emigrated DC. Skin explants were i.d. injected
with medium or the indicated cytokines and cultured for 2 days at which time explants were discarded. Migrated cells were harvested at day 2 or 7,
thoroughly washed, and stimulated by CD40L-expressing J558 cells in the presence of IFNc (1000 IU/ml). Supernatants were harvested 24 hr later
and IL-10 and IL-12p70 concentrations determined by ELISA. A) Cytokine release is shown in pg/ml per 10,000 cells per 24 h for the indicated
conditions and time points. Means 6s.e.m. from 6–7 experiments are shown. B) Mean IL-12p70 and IL-10 concentrations were divided to obtain IL-
12:IL-10 ratios for the indicated cytokine conditions and time points (N= 6–7). The obtained ratios are displayed in relation to CD83 and CCR7
expression on the skin explant-emigrated DC at day 7 after the start of explant culture (mean fluorescence intensities are listed and corresponding
isotype control levels marked). Asterisks denote significant differences (*P,0.05, **P,0.01).
doi:10.1371/journal.pone.0070237.g006
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skin emigrated and anti-CD3 loaded DC with unsorted allogeneic
peripheral blood lymphocytes, highest frequencies of CD25hi-
FoxP3+ Tregs were observed in cultures with DC emigrated from
IL-10 conditioned skin explants (Fig. 7E, n= 3 open symbols).
Whereas intracellular IFNc expression upon activation with PMA
and ionomycin was observed in FoxP32 Th cells in these cultures,
this was not the case for the CD25hiFoxP3+ cells (Fig. 7F),
providing further functional evidence of their Tr1/Treg identity.
To confirm the actual induction/conversion of Tr1/Tregs from
conventional CD4+ T cells, cells from 14-day co-cultures with
sorted allogeneic CD252 Th cells were also stained for CD25 and
intracellular FoxP3 expression. As demonstrated by Fig. 7G,
CD25hiFoxP3+ Tr1/Tregs were induced only by DC emigrated
from IL-10 conditioned skin (n = 2, closed symbols in Fig. 7E).
Cytokine-mediated conditioning of the dermis: effects on
CD8+ effector T cell priming
To assess the effects of cytokine-modulated DC subset migration
on CD8+ effector T cell priming, migrated DC from HLA-A2+
explants were loaded with the immune-dominant Mart-1-derived
epitope Mart-1aa26L235 and cultured with HLA-A2-matched
allogeneic CD8b+ T cells. Multiple parallel bulk cultures per
condition (n= 3–6) were set up with DC from three different skin
donors. After 10 days specific expansion of Mart-1aa26L235
reactive CD8+ T cells was checked by HLA-tetramer staining.
Combined data from the three priming experiments are shown in
Fig. 8A. After this one round of stimulation, tetramer positive
cultures were exclusively found after stimulation by DC from GM-
CSF+IL-4-conditioned skin for all 3 donors tested (1/4, 4/6, and
2/5 positive cultures, respectively). In one donor massive T cell
death in the IL-10-modulated DC cultures precluded reliable
tetramer analysis. T cells were subsequently re-stimulated with
peptide-loaded JY cells and seven days later re-analyzed for
tetramer binding (Fig. 8B). Even then no tetramer positive cultures
were observed for the IL-10 conditions, whereas in one donor a T
cell bulk primed by medium control DC did bind tetramers, albeit
at a low intensity, suggestive of low T cell receptor binding affinity.
This was borne out by functional avidity analysis, showing half-
maximal IFNc release by these tetramer positive T cells at
approximately 100-fold higher peptide concentrations than T cells
primed by DC from GM-CSF+IL-4-conditioned skin (see Fig. 8C).
Discussion
Most of our knowledge of the functionality of skin DC subsets
has been gleaned from mouse studies. In human skin, functional
studies have been hampered by low DC numbers and by the
inability to manipulate them in a targeted fashion, as has been
achieved in mice through conditional knock-out of specific DC
subsets [30]. Much of what we do know of human skin subsets has
been the result of research on the dermal delivery of cancer
vaccines, in which new avenues have been explored to specifically
target cutaneous DC subsets with the ability to efficiently prime
Th1 and CTL responses [31]. Tumor-induced systemic suppres-
sion of DC development and maturation may well interfere with
these functions. We previously showed the effects of the cancer-
associated suppressive cytokine IL-10 on the phenotype and
allogeneic T cell priming ability of human skin-emigrated DC
[19]. In the current study we more extensively profiled various
DDC subsets and studied the effects of cancer-related and
cytokine-mediated conditioning of the human dermis on the
subset composition and phenotype of the skin-emigrating DC
population in relation to the induction and skewing of CD4+ and
CD8+ T cell differentiation. Although the numbers of migrated
cells were too low to allow for sorting of the different subsets, our
findings show dramatic shifts in the relative migration rates of the
DC subsets with clear impact on the induction of both functional
Th and CD8+ T cells.
In keeping with findings by others (reviewed by Teunissen et al.
[32]), intracellular staining for Langerin and E-Cadherin positively
identified the CD1ahi subset among the human skin explant-
emigrated DC as LC, while intracellular expression of DC-SIGN
identified the five remaining subsets as DDC (either CD1a+ and/
or CD14+, or DN). DC-SIGN was upregulated by i.d. adminis-
tration of GM-CSF and IL-4 in all five DDC subsets. This up-
regulation was most likely dependent on IL-4, previously shown to
be primarily responsible for the induction of DC-SIGN [33].
Interestingly, cytokine conditioning mostly affected the migratory
balance between the CD1a+ and CD14+ skin DC subsets, more so
than their general maturation state, and apparently left the
migration rates of both DN DDC subsets relatively unaffected.
Importantly, the CD14+ DDC subsets were phenotypically
immature, characterized by high levels of BDCA3/CD141, a
marker recently associated with DC subsets with cross-presenta-
tion abilities [27], and their relative migration rates were increased
by dermal IL-10 conditioning. In a comparative analysis with
CD142 DDC, CD14+ DDC were previously shown to be poor
inducers of allogeneic T cells and to require high DC:T cell ratios
for Th1 induction [14]. Here we show that dermal conditioning by
IL-10 increased their PD-L1 expression levels, while maintaining
low levels of co-stimulatory molecules, and led to high IL-10
release levels upon CD40L-mediated stimulation. This resulted in
Th2 and Tr1/Treg induction, accompanied by IL-10 transcrip-
tion and release upon co-culture with CD4+CD252 T cells, and an
inability to prime CD8+ effector T cells. In keeping with these
observations, Banchereau et al. have recently shown that IL-10
released by CD14+ DDC into the immune synaps is mainly
responsible for their inability to prime functional CTL [8], while
interference with Immunoglobulin-like transcript inhibitory recep-
tors (ILT) inhibits their type-2 cytokine skewing ability [34].
Figure 7. Effects of dermal cytokine conditioning on the induction of Th cell differentiation by skin-emigrated DC. Two days after
injection of medium with or without cytokines, skin-emigrated DC were harvested, pulsed with anti-CD3 and co-cultured for 2 weeks with
CD4+CD252 allogeneic T cells. A) Th cell expansion factors after 2 weeks of co-culture. B) Cytokine release levels (measured after 24 h stimulation
with anti-CD3/anti-CD28, n = 4; mean6s.e.m.) and C) IL-10 release and relative IL-10 and FoxP3 mRNA expression levels (n = 3, mean6s.e.m) of the
primed Th cells. Significant differences in appropriate paired statistical tests were determined versus medium controls (unless otherwise indicated)
and denoted by asterisks: *P,0.05, **P,0.01. D) Correlation between CD1a+CD14+ and CD1a+CD142 DDC frequencies among skin-emigrated DC (for
all tested conditions, n = 3) and FoxP3 and IL-10 transcript levels (statistical analysis by Pearson correlation). E) Superior expansion and/or induction of
CD25hiFoxP3+ Tregs by DC migrated from IL-10 conditioned skin explants; open symbols: skin-emigrated DC from three donors were co-cultured with
unsorted allogeneic lymphocytes; closed symbols: skin-emigrated DC from two donors were co-cultured with sorted CD4+CD252 T cells. *P,0.05,
**P,0.01 in a repeated measures ANOVA with Tukey post-hoc test. F) FoxP3 versus IFNc expression in allogeneic CD4+CD3+ T cells (both by
intracellular staining upon PMA/ionomycin stimulation for 4 hours), primed by DC migrated from conditioned human skin explants and G)
flowcytometric Treg analysis in 14-day co-cultures of migrated skin DC with allogeneic CD4+CD252 T cells; test conditions and percentages of FoxP3+
or IFNc+ CD4+ T cells or of CD25hiFoxP3+ Tregs are indicated.
doi:10.1371/journal.pone.0070237.g007
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Of note, our previous [19] and current findings, identifying
CD14+BDCA3/CD141+ DC as an immature migratory subset
with immune regulatory properties, are in line with a recent report
by Chu et al. showing IL-10 release and functional Treg induction
by the same subset with suppressive effects on skin inflammation
[18], suggesting a role in the maintenance of homeostatic
tolerance. In addition we now show an increased frequency of
the CD14+ DDC subset among DC migrating from IL-10- and
cancer-conditioned skin. Of particular interest in this context is the
IL-10-induced upregulation of the M2-macrophage associated
marker CD163 on CD14+ migratory DDC. This marker was
previously reported on skin-resident macrophages [35], which
were also found to express DC-SIGN. Although DC-SIGN and
CD163 are both expressed by the CD14+ DDC, which, moreover,
functionally and morphologically resemble macrophages [19], we
have nevertheless designated them DC, because 1) they are
migratory unlike dermal macrophages which are generally
regarded as sessile [36], 2) they express BDCA1/CD1c [19], a
typical feature of DDC [35] and 3) because they can develop from
migrated CD1a+ DC through a CD1a+CD14+ intermediate
(designated DDC subset 3 in this study –see Fig. 1 and 2) [19].
The latter observation raises an important issue that as yet remains
unresolved: are the observed sub-populations among the migrated
human DDC genuine subsets, or rather representations of the
same DDC in various states of (trans-)differentiation? Indeed, we
have previously found compelling evidence, both from cytokine-
conditioned and irritant-treated skin explants, that LC and CD1a+
DDC can trans-differentiate during migration to the CD14+
macrophage-like DDC subset in an IL-10-dependent fashion
[19,37]. Conversely, Larregina et al. reported the differentiation of
LC from dermal CD14+ precursors [38]. Finally, it has even been
suggested that an inflammatory environment in the dermis may
lead to the trans-differentiation of sessile macrophages to
migratory (CD14+) DDC, possibly accounting for the observed
reduced densities of macrophages in human skin explants upon
culture [31,38]. Altogether these studies paint a picture of an inter-
related population of dermal DC and macrophages in flux, trans-
differentiating into each other, as dictated by environmental
conditions. Indeed, the IL-10-conditioned CD14+ DDC with a
DC-SIGN+BDCA3+CD163+ phenotype are highly reminiscent of
both tumor-associated macrophages and DC, adopting similar
M2-like immunosuppressive traits [39–41]. As a model for cancer-
induced suppression of DC in the skin microenvironment, we also
studied the migration of DC from explants derived from skin
overlying breast tumors, for which a reduced LC density was
previously reported [42]. Similarly to the IL-10-modulated skin
explants, a remarkable shift to immature CD14+ DDC migration
was observed in these skin explants, taken from mastectomy
specimens from chemo-naive patients. The small size of the skin
specimens obtained from these patients precluded neutralization
experiments to identify the responsible suppressive factor. How-
ever, testing a panel of tumor-associated culprits pointed to IL-10
as the most likely candidate, since it was the only tested cytokine
that could affect the balance of migrating CD1a+ and CD14+
DDC. This is in keeping with other reports demonstrating the
unique ability of IL-10 among other suppressive factors to
modulate the maturation and migration of fully differentiated
DC [40,43,44]. Importantly, reduction of tumor load by
neoadjuvant chemotherapy led to normalization of the migratory
DDC subset distribution, providing evidence for tumor involve-
ment in the observed aberrant migration of predominantly CD14+
DDC.
In contrast to IL-10, i.d. delivery of GM-CSF+IL-4 effected
predominant migration of CD1a+ DDC and LC and resulted in
Figure 8. Efficient priming of high-avidity CD8+ T effector cell
by skin-emigrated DC upon dermal conditioning with GM-
CSF+IL-4. A) Multiple parallel bulk cultures were set up of HLA-A2
matched allogeneic CD8b+ T cells from three different donors together
with Mart-126L235 peptide loaded DC, emigrated from skin explants that
were i.d. injected by medium or cytokines as indicated. Ten days later
Mart-126L2352specific T cell frequencies were determined in all bulk
cultures by HLA-tetramer (Tm) binding. Aggregate results from all 3
experiments are shown. *P,0.05, **P,0.01 in Fisher’s Exact test. B)
Seven days after restimulation with Mart-126L235 peptide loaded JY
cells, Tm positive cultures were pooled. Sufficient numbers were
obtained from one T cell donor to undertake functional avidity analyses
for the medium and GM-CSF+IL-4 conditions. Tm binding levels in these
two bulk cultures are shown (MFI: Mean Fluorescence Intensity). Note:
no Tm positive cultures were obtained for any of the IL-10 conditions.
C) Stimulation of the pooled bulk cultures with JY cells, loaded with
titrated amounts of the Mart-126L235 peptide, followed by intracellular
IFNc expression read-out, showed CD8+ effector T cells from the GM-
CSF+IL-4 condition to be of higher avidity than those from the medium
condition (half-maximal frequencies of IFNc producing Tm+ T cells for
both test conditions and the corresponding peptide concentrations
used for JY loading are indicated by arrows).
doi:10.1371/journal.pone.0070237.g008
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Th1 induction (evidenced by increased IFNc release levels). In
addition, GM-CSF+IL-4-modulated DDC and LC were superior
inducers of anti-melanoma CD8+ effector T cells, which were
shown to exhibit increased functional avidity. Klechevsky et al. first
reported a functional dichotomy between human LC and CD14+
DDC with the former preferentially activating CTL and the latter
B cell responses [45]. Our own genome-wide transcriptional
profiling studies of LC versus CD1a+ DDC, clearly showed the
latter to be more activated under steady state conditions [46]. In
keeping with findings by others, our studies show that LC only
make up a small minority of the ‘‘crawl-out’’ DC derived from
cultured full-thickness skin explants (typically between 1–5%) [32].
While i.d. delivery of GM-CSF and IL-4 prior to culture increased
this frequency to about 10%, their relative under-representation in
the tested conditions leaves the exact contribution of LC to the
observed effects on T cell induction in doubt. Nevertheless, our
current findings that IL-10-induced increases in CD14+ DDC
migration correspond to increased Th2/Treg skewing and that
GM-CSF+IL-4-induced increases in LC and CD1a+ DDC
migration correspond to efficient and high-avidity CD8+ T cell
priming, are in line with the observations made by Klechevsky et al
[8,45].
Whereas default Th1 induction by skin DC was previously
shown to depend on IL-23 rather than IL-12p70 release [14], we
found evidence for a GM-CSF and IL-4-induced release of IL-
12p70 which most likely accounts for the increased induction and
expansion of Th1 and high-avidity CD8+ effector T cells. Several
reports have indicated that in vitro generated LC as well as primary
LC and DDC, isolated from human skin, are poor IL-12p70
producers [7,9,47]. Our data indicate that LC and/or DDC are
capable of high-level IL-12p70 release upon intracutaneous
activation by GM-CSF and IL-4, but only at late time points
following migration, i.e. after 5 to 7 days. This is in sharp contrast
to previous findings for in vitro cultured MoDC, which reach a so-
called ‘‘exhausted’’ state 48 h post-stimulation, resulting in an
inability to release IL-12p70 and to induce Th1 cells and CTL
[48,49]. Preferred early IL-12p70 release is in keeping with the
proposed acute inflammatory role of MoDC in vivo [50]. In
contrast, skin-resident DC, with a very low turn-over and
migration rate [51], predominantly release IL-10 under steady
state conditions. Only in the presence of strong maturational
signals such as the pro-inflammatory cytokines GM-CSF and IL-4,
which induce a mature phenotype that can be sustained for up to 7
days following the initiation of migration, do skin-emigrated DC
release high levels of IL-12p70 in response to CD40L stimulation,
and then contribute to the induction of type-1 T cell-mediated
immunity. IL-10/IL-12p70 release kinetics thus indicate a
powerful default tolerance maintained by migrating skin DC that
can only be lifted by strong activating signals resulting in durable
DC maturation.
Finally, and remarkably, i.d. delivery of either IL-10 or GM-
CSF/IL-4 resulted in down-regulated transcription and release
of IL-22. In view of the respective inhibitory and stimulatory
effects of IL-10 and GM-CSF+IL-4 on type-1 T cell activation,
this observation is in keeping with the recognized role of IL-22
in skin homeostasis and inflammation as well as its apparent
minor role in cell-mediated immunity against viruses and/or
cancer [52].
In conclusion, IL-10 conditioning of human skin leads to
predominant migration of immature CD14+BDCA3/CD141+
DDC subsets, which display a suppressive M2-like phenotype,
i.e. low co-stimulatory marker levels combined with up-regulated
PD-L1 and CD163, and dominant IL-10 release, and which do
not support CD8+ effector T cell expansion, but rather induce
type-2 and IL-10 producing Th cells as well as CD25hiFoxP3+
Tregs. In contrast, GM-CSF+IL-4 conditioning leads to predom-
inant migration of CD1a+ LC and DDC subsets in a sustained
mature state that predominantly release IL-12p70 and can induce
both Th1 and tumor-specific CD8+ high-avidity effector T cells.
Our data suggest overriding immune suppressive effects of IL-10
in tumor-conditioned skin and argue in favor of the incorporation
of GM-CSF and IL-4 in adjuvants for transcutaneously or
intradermally delivered cancer vaccines.
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